Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Dec. 16, 2011 - PRLog -- GlobalData’s analysis shows that the global candidiasis therapeutics market was worth $1,992.7m in 2005 and grew at Compound Annual Growth Rate (CAGR) of 11.8% to $3,476.9m in 2010. GlobalData forecasts that the market will grow at a CAGR of 5.6% to reach $5,388.9m by 2018. The current competitive landscape consists of azoles, echinocandins and polyenes. The azoles class comprises products such as fluconazole, itraconazole, clotrimazole, voriconazole, ketoconazole and posoconazole.
Most of the drugs in the azoles class are generics, and the only branded product is posoconazole, under the brand name Noxafil. The drugs in the polyenes class are also generics. The only class which consists entirely of branded products is echinocandins, namely ERAXIS (anidulafungin), Mycamine (micafungin) and Cancidas (caspofungin).

The moderate market growth is attributed to the fact that the market is dominated by generic products and has a weak pipeline with only one company-sponsored first-in-class molecule (isavuconazole) in the late stage of development.

The forecast growth can be attributed to the increase in the candidiasis patient population due to the increasing number of immunocompromised patients.

GlobalData’s analysis shows that competition in the candidiasis therapeutics market is strong. The current market landscape comprises more than 10 marketed products in three classes: azoles, polyenes and echinocandins. The polyene and azole classes have been used the longest to treat the various types of Candida infection and are quite successful in meeting therapeutic need, with high efficacy and safety profiles. They are available in different dosage forms and have high patient compliance rates. Echinocandins are available in an Intravenous (IV) dosage form and have medium to high levels of efficacy. All of the products are able to cure Candida infection in most cases, and as such, the unmet need in the candidiasis therapeutics market is low.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

Unmet need does exist however in terms of relapse of fungal infection, which usually occurs following treatment with currently-used antifungals. There is a need for first-in-class antifungals which can treat the infection without the fear of relapse.

Unmet need is 13-20% in the overall candidiasis therapeutics market, which is divided into four types:
•   Oropharyngeal candidiasis
•    Esophageal candidiasis
•   Systemic candidiasis
•   Vaginal candidiasis

GlobalData, the industry analysis specialist, has released its new report, “Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global candidiasis therapeutics market. The report identifies the key trends shaping and driving the global candidiasis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis therapeutics market sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Cand...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.